readthroughSign in
Aug 19, 2026Trial update

Enanta posts results for Phase 2b EDP-938 RSV trial in high-risk adults

Enanta Pharmaceuticals reported results for a completed Phase 2b study of oral EDP-938 in non-hospitalized adults with RSV at high risk of complications.

Enanta Pharmaceuticals had one update this week, with results posted for its Phase 2b RSV trial.

  • The Phase 2b, randomized, double-blind, placebo-controlled study tested oral EDP-938 in non-hospitalized adults with confirmed RSV infection who were at high risk for post-infection complications.1 The study, sponsored by Enanta Pharmaceuticals, is listed as completed, with primary completion and study completion both dated 2025-06-23, and results were first posted 2026-08-19. The trial enrolled 187 participants.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.